Lymphopenia adverse event reports that record this term

Kind of term: MedDRA preferred term

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From January 2004 to June 2026, FDA received 13,866 adverse event reports that record the MedDRA preferred term Lymphopenia. The person who codes a report selects the term that agrees best with the description of the reporter.

FDA received 919 reports in the 12 months to June 2026 and 873 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

By reports in the 12 months to June 2026, this term was number 647 of 1,436 reaction terms with a page. Of the 1,332,454 drug reports that FDA received in the 12 months to June 2026, 919 (0.1%) record this term. Reports for female patients were 46.4% of the reports that record this term and 52.7% of all drug reports.

The number of people who use the product is not in the data. A count is not a rate.

MedDRA

The Medical Dictionary for Regulatory Activities. The person who codes a report selects the preferred term that agrees best with the description of the reporter. FDA does not publish the description.

Data version

openFDA FAERS release of 29 Oct 2026. Reports received through 30 Jun 2026.

Drugs in these reports

The table has the 121 drug pages with 50 or more reports that record this term. The rows are in order of name. A drug page with fewer reports for this term is not in the table. The counts are the counts that the site keeps for each reaction term, and a count can be lower than the count of FDA.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Drugs that the reports with the term Lymphopenia name as a suspect product, in order of name
Drug	Class	Reports with this term
Acetaminophen		65
Actemra	Interleukin-6 receptor antagonist	68
Acyclovir	Herpes simplex virus nucleoside analog DNA polymerase inhibitor	72
Adalimumab	Tumor necrosis factor blocker	94
Alemtuzumab	CD52-directed cytolytic antibody	262
Allopurinol	Xanthine oxidase inhibitor	129
Asparaginase		58
Aubagio	Pyrimidine synthesis inhibitor	77
Azathioprine	Purine antimetabolite	342
Bactrim	Dihydrofolate reductase inhibitor antibacterial	150
Basiliximab	Interleukin-2 receptor blocking antibody	60
Bendamustine		157
Bendamustine hydrochloride	Alkylating drug	74
Bevacizumab	Vascular endothelial growth factor inhibitor	271
Bortezomib	Proteasome inhibitor	174
Capecitabine	Nucleoside metabolic inhibitor	115
Carbamazepine	Mood stabilizer	73
Carboplatin	Platinum-based drug	306
Carfilzomib	Proteasome inhibitor	175
Cefazolin	Cephalosporin antibacterial	62
Celecoxib	Nonsteroidal anti-inflammatory drug	60
CellCept	Antimetabolite immunosuppressant	100
Cetuximab	Epidermal growth factor receptor antagonist	50
Chlorambucil	Alkylating drug	50
Cholecalciferol		71
Cisplatin	Platinum-based drug	306
Cladribine	Purine antimetabolite	77
Clozapine	Atypical antipsychotic	59
Cyclophosphamide	Alkylating drug	1,154
Cyclosporine	Calcineurin inhibitor immunosuppressant	253
Cytarabine	Nucleoside metabolic inhibitor	284
Daratumumab	CD38-directed cytolytic antibody	117
Darzalex	CD38-directed cytolytic antibody	108
Daunorubicin		99
Daunorubicin hydrochloride	Anthracycline topoisomerase inhibitor	68
Dexamethasone	Corticosteroid	897
Dimethyl fumarate		70
Docetaxel	Microtubule inhibitor	123
Doxorubicin	Anthracycline topoisomerase inhibitor	336
Doxorubicin hydrochloride	Anthracycline topoisomerase inhibitor	175
Erbitux	Epidermal growth factor receptor antagonist	61
Ergocalciferol	Provitamin D2 compound	71
Etoposide	Topoisomerase inhibitor	448
Everolimus	Kinase inhibitor	68
Fasturtec		67
Fenofibrate	Peroxisome proliferator receptor alpha agonist	60
Filgrastim	Leukocyte growth factor	160
Fingolimod	Sphingosine 1-phosphate receptor modulator	444
Fluconazole	Azole antifungal	57
Fludarabine	Nucleoside metabolic inhibitor	217
Fludarabine phosphate	Nucleoside metabolic inhibitor	69
Fluorouracil	Nucleoside metabolic inhibitor	138
Furosemide	Loop diuretic	120
Gabapentin	Anti-epileptic agent	68
Ganciclovir	Cytomegalovirus nucleoside analog DNA polymerase inhibitor	55
Gemcitabine	Nucleoside metabolic inhibitor	124
Gilenya	Sphingosine 1-phosphate receptor modulator	1,205
Hydrocortisone	Corticosteroid	73
Hydroxychloroquine	Antimalarial	128
Ibrance	Kinase inhibitor	63
Ibrutinib (form s4)	Kinase inhibitor	91
Ifosfamide	Alkylating drug	100
Imbruvica	Kinase inhibitor	60
Infliximab	Tumor necrosis factor blocker	65
Irinotecan		57
Isatuximab	CD38-directed cytolytic antibody	71
Kesimpta	CD20-directed cytolytic antibody	60
Kisqali	Kinase inhibitor	65
Lamotrigine	Anti-epileptic agent	53
Lansoprazole	Proton pump inhibitor	87
Lemtrada	CD52-directed cytolytic antibody	188
Lenalidomide	Thalidomide analog	207
Letrozole	Aromatase inhibitor	97
Levetiracetam		61
Levofloxacin	Fluoroquinolone antibacterial	53
Lovenox	Low molecular weight heparin	65
Mabthera		138
Mavenclad	Purine antimetabolite	142
Mayzent	Sphingosine 1-phosphate receptor modulator	186
Melphalan	Alkylating drug	119
Mercaptopurine	Nucleoside metabolic inhibitor	87
Methotrexate	Folate analog metabolic inhibitor	559
Methotrexate sodium	Folate analog metabolic inhibitor	102
Methylprednisolone	Corticosteroid	336
Metoclopramide hydrochloride	Dopamine-2 receptor antagonist	53
Mycamine		71
Mycophenolate mofetil	Antimetabolite immunosuppressant	494
Mycophenolic acid	Antimetabolite immunosuppressant	94
Ocrelizumab	CD20-directed cytolytic antibody	100
Ocrevus	CD20-directed cytolytic antibody	167
Ondansetron	Serotonin-3 receptor antagonist	60
Oxaliplatin	Platinum-based drug	110
Paclitaxel	Microtubule inhibitor	289
Pantoprazole	Proton pump inhibitor	105
Pembrolizumab	Programmed death Receptor-1 blocking antibody	50
Pomalidomide	Thalidomide analog	107
Prednisolone	Corticosteroid	555
Prednisone	Corticosteroid	907
Ramipril	Angiotensin converting enzyme inhibitor	67
Revlimid	Thalidomide analog	159
Ribavirin	Nucleoside analog antiviral	59
Rituxan	CD20-directed cytolytic antibody	57
Rituximab	CD20-directed cytolytic antibody	997
Sirolimus	Kinase inhibitor	78
Sulfamethoxazole, trimethoprim	Dihydrofolate reductase inhibitor antibacterial	83
Tacrolimus	Calcineurin inhibitor immunosuppressant	465
Tecfidera		540
Temodar	Alkylating drug	84
Temozolomide	Alkylating drug	255
Thalidomide		125
Thymoglobulin	Immunoglobulin G	60
Trastuzumab	HER2/neu receptor antagonist	103
Tysabri	Integrin receptor antagonist	55
Valganciclovir	Cytomegalovirus nucleoside analog DNA polymerase inhibitor	96
Velcade	Proteasome inhibitor	129
Venetoclax	BCL-2 inhibitor	79
Vincristine		388
Vincristine sulfate	Vinca alkaloid	136
Vumerity		56
Zeposia	Sphingosine 1-phosphate receptor modulator	84
Zinecard		68

The page of each drug has the count of each reaction term in its reaction lookup.

Drug classes in these reports

The table has the 45 pharmacologic classes with 100 or more reports that record this term. The rows are in order of name.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Pharmacologic classes of the drugs that the reports with the term Lymphopenia name, in order of name
Class	Reports with this term
Alkylating drug	1,983
Anthracycline topoisomerase inhibitor	609
Anti-epileptic agent	194
Antimalarial	158
Antimetabolite immunosuppressant	708
Antimycobacterial	100
Aromatase inhibitor	138
Atypical antipsychotic	275
Azole antifungal	114
beta2-Adrenergic agonist	101
Bisphosphonate	112
Calcineurin inhibitor immunosuppressant	783
CD20-directed cytolytic antibody	1,449
CD38-directed cytolytic antibody	296
CD52-directed cytolytic antibody	483
Cephalosporin antibacterial	155
Corticosteroid	2,979
Cytomegalovirus nucleoside analog DNA polymerase inhibitor	155
Dihydrofolate reductase inhibitor antibacterial	275
Epidermal growth factor receptor antagonist	123
Fluoroquinolone antibacterial	108
Folate analog metabolic inhibitor	692
HER2/neu receptor antagonist	134
Interleukin-6 receptor antagonist	118
Janus kinase inhibitor	143
Kinase inhibitor	900
Leukocyte growth factor	248
Loop diuretic	139
Microtubule inhibitor	475
Mood stabilizer	101
Nonsteroidal anti-inflammatory drug	191
Nucleoside metabolic inhibitor	1,107
Osmotic laxative	111
Platinum-based drug	722
Programmed death Receptor-1 blocking antibody	176
Proteasome inhibitor	526
Proton pump inhibitor	281
Purine antimetabolite	590
Sphingosine 1-phosphate receptor modulator	1,956
Thalidomide analog	491
Topoisomerase inhibitor	519
Tumor necrosis factor blocker	283
Vascular endothelial growth factor inhibitor	316
Vinca alkaloid	147
Xanthine oxidase inhibitor	129

A class with many reports in all has many reports for almost every term.

Reports by month

Reports that record Lymphopenia, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Patients in these reports

Age of the patient in the reports that record Lymphopenia
Age	Reports	Share
Under 2	131	0.9%
2 to 11	416	3%
12 to 17	248	1.8%
18 to 44	2,577	18.6%
45 to 64	3,624	26.1%
65 to 74	1,593	11.5%
75 and over	980	7.1%
Age not given	4,297	31%

Sex of the patient in the reports that record Lymphopenia
Sex	Reports	Share
Female	6,430	46.4%
Male	4,950	35.7%
Unknown or not given	2,486	17.9%

Age and sex are as the report gives them. 26.8% of these reports give the United States as the country.

Terms near this one

These are the next terms in the A to Z list. The links are for navigation.

Official pages

MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Lymphopenia: adverse event reports that record this term. https://reportedreactions.com/reaction/lymphopenia/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 29 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 29 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Nov 2026. A class is the pharmacologic class (EPC) of the FDA label.

The count has the reports with each spelling of one MedDRA preferred term. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

What does Lymphopenia mean in an adverse event report?

It is a MedDRA preferred term. FDA codes the description of a reporter with the MedDRA dictionary. The openFDA files do not have the description itself, and this site does not show it.

Does a drug in the table mean that the drug was responsible for this reaction?

No. FDA says:

No individual drug is connected to any individual reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

What does this page tell a person who has this symptom?

This page gives counts of reports. It cannot assess a person. A pharmacist or a clinician can assess a person.

If this is a medical emergency, please call 911.
Source: FDA, MedWatch Online Voluntary Reporting Form. The site read the page on 2 Oct 2026.

To the top of the page